Lytix Biopharma AS (OSL:LYTIX)

Norway flag Norway · Delayed Price · Currency is NOK
8.60
-0.08 (-0.92%)
Jun 6, 2025, 4:25 PM CET
25.00%
Market Cap 587.05M
Revenue (ttm) 608.00K
Net Income (ttm) -89.01M
Shares Out 68.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,650
Average Volume 208,020
Open 8.60
Previous Close 8.68
Day's Range 8.20 - 8.64
52-Week Range 4.55 - 15.00
Beta -0.37
RSI 73.44
Earnings Date May 15, 2025

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 8
Stock Exchange Oslo Børs
Ticker Symbol LYTIX
Full Company Profile

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.

Financial Statements

News

There is no news available yet.